Precision Medicine in Non-Hodgkin Lymphoma: Advances in BTK Inhibition, CD30-Directed Antibody–Drug Conjugates, and HDAC-Mediated Epigenetic Therapy with Pirtobrutinib, Brentuximab Vedotin, and Belinostat.
Saved in:
| Title: | Precision Medicine in Non-Hodgkin Lymphoma: Advances in BTK Inhibition, CD30-Directed Antibody–Drug Conjugates, and HDAC-Mediated Epigenetic Therapy with Pirtobrutinib, Brentuximab Vedotin, and Belinostat. |
|---|---|
| Authors: | Kawczak, Piotr1 (AUTHOR) piotr.kawczak@gumed.edu.pl, Bączek, Tomasz1,2 (AUTHOR) |
| Source: | Journal of Clinical Medicine. Jun2026, Vol. 15 Issue 12, p4425. 45p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
